dc.contributor.author |
Berastegui García, Cristina |
dc.contributor.author |
Gómez-Ollés, Susana |
dc.contributor.author |
Mendoza-Valderrey, Alberto |
dc.contributor.author |
Pereira-Veiga, Thais |
dc.contributor.author |
Culebras Amigo, Mario |
dc.contributor.author |
Monforte, Víctor |
dc.contributor.author |
Sáez-Giménez, Berta |
dc.contributor.author |
López-Meseguer, Manuel |
dc.contributor.author |
Sintes-Permanyer, Helena |
dc.contributor.author |
Ruiz de Miguel, Victoria |
dc.contributor.author |
Bravo, Carlos |
dc.contributor.author |
Sacanell, Judith |
dc.contributor.author |
Ramon, María-Antonia |
dc.contributor.author |
Romero, Laura |
dc.contributor.author |
Deu, Maria |
dc.contributor.author |
Román, Antonio |
dc.contributor.author |
Universitat Autònoma de Barcelona |
dc.date |
2020 |
dc.identifier |
https://ddd.uab.cat/record/252403 |
dc.identifier |
urn:10.1371/journal.pone.0226488 |
dc.identifier |
urn:oai:ddd.uab.cat:252403 |
dc.identifier |
urn:pmcid:PMC6957146 |
dc.identifier |
urn:pmc-uid:6957146 |
dc.identifier |
urn:pmid:31929536 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:6957146 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
PloS one ; Vol. 15 (january 2020) |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.title |
Use of serum KL-6 level for detecting patients with restrictive allograft syndrome after lung transplantation |
dc.type |
Article |
dc.description.abstract |
KL-6 is an antigen produced mainly by damaged type II pneumocytes that is involved in interstitial lung disease. Chronic lung allograft dysfunction (CLAD) after lung transplantation (LT) is a major concern for LT clinicians, especially in patients with restrictive allograft syndrome (RAS). We investigated KL-6 levels in serum and bronchoalveolar lavage fluid (BALF) as a potential biomarker of the RAS phenotype. Levels of KL-6 in serum and BALF were measured in 73 bilateral LT recipients, and patients were categorized into 4 groups: stable (ST), infection (LTI), bronchiolitis obliterans syndrome (BOS), and RAS. We also studied a healthy cohort to determine reference values for serum KL-6. The highest levels of KL-6 were found in the serum of patients with RAS (918 [487.8-1638] U/mL). No differences were found for levels of KL-6 in BALF. Using a cut-off value of 465 U/mL serum KL-6 levels was able to differentiate RAS patients from BOS patients with a sensitivity of 100% and a specificity of 75%. Furthermore, higher serum KL-6 levels were associated with a decline in Forced Vital Capacity (FVC) at 6 months after sample collection. Therefore, KL-6 in serum may well be a potential biomarker for differentiating between the BOS and RAS phenotypes of CLAD in LT recipients |